Item 1.02 Termination of a Material Definitive Agreement.
On January 20, 2020 Regen Biopharma, Inc. (the "Company") and BST Partners Inc.
agreed that the month to month sublease by and between the Company and BST
Partners, Inc. whereby the Company subleased office space from BST Partners,
Inc.at 4700 Spring Street, St 304, La Mesa, California 91942 shall terminate as
of 1pm Pacific Standard Time on January 22, 2020.
Item 5.02 Departure of Directors or Certain Officers
On January 22, 2020 David Koos resigned as Chairman of the Board of Directors,
Chief Executive Officer of and from any and all offices held at Regen Biopharma,
Inc. (the "Company") as of 1 pm Pacific Standard Time on January 22, 2020 (
"Effective Date and Time"). As of the Effective Date and Time Todd S. Caven, the
Company's Chief Financial Officer and a member of the Board of Directors of the
Company, shall be the Company's sole officer and member of the Company's Board
of Directors.
On January 22, 2020 David Koos resigned as Chairman of the Board of Directors,
Chief Executive Officer of and from any and all offices held at KCL
Therapeutics, Inc. (KCL) as of 1 pm Pacific Standard Time on January 22, 2020 (
"Effective Date and Time"). As of the Effective Date and Time Todd S. Caven,
KCL's Chief Financial Officer and a member of the Board of Directors KCL, shall
be KCL's sole officer and member of KCL's Board of Directors.
Item 9.01 Exhibits
Exhibit 99.1 Letter of resignation
Exhibit 99.2 Termination of Sublease
2
© Edgar Online, source Glimpses
REGEN BIOPHARMA, INC. 
